基于T细胞的免疫年龄指标可预测接受达雷妥尤单抗为基础治疗的老年骨髓瘤患者结局
研究对HOVON-143和CASSIOPEIA/HOVON-131试验中124例>65岁和145例≤65岁初诊多发性骨髓瘤患者进行外周血和骨髓T细胞及自然杀伤细胞的高维流式分析,发现老年患者T细胞更活化、分化及衰老,但个体差异大,遂基于T细胞表型数据构建免疫时钟量化免疫年龄;在老年非fit初诊患者中,免疫年龄对达雷妥尤单抗-伊沙佐米-地塞米松治疗结局的预测强于日历年龄,即使校正衰弱等风险因素后仍如此。
要点
- 老年多发性骨髓瘤患者T细胞更活化、分化及衰老,但个体差异大。
- 基于高维T细胞表型数据构建免疫时钟可量化个体免疫年龄。
- 在老年非fit初诊患者中,免疫年龄对治疗结局的预测强于日历年龄。
核心结论
- 免疫年龄是比日历年龄更能反映患者免疫状态的临床相关复合指标,可能有助于预测老年多发性骨髓瘤或其他血液肿瘤患者的免疫治疗疗效。
研究设计与样本
- 对HOVON-143和CASSIOPEIA/HOVON-131试验中124例>65岁和145例≤65岁初诊多发性骨髓瘤患者(年龄34-92岁)的外周血和骨髓样本进行T细胞和自然杀伤细胞的高维流式细胞术分析。
主要发现
- 老年患者平均表现出比年轻患者更活化、分化和衰老的T细胞 compartment。
- 两个年龄组内T细胞亚群频率均存在显著个体间差异,表明日历年龄不足以反映个体免疫状态。
- 基于高维T细胞表型数据构建免疫时钟,发现日历年龄相似的患者免疫年龄存在显著差异。
- 在老年非fit初诊多发性骨髓瘤患者中,免疫年龄对达雷妥尤单抗-伊沙佐米-地塞米松治疗结局的预测强于日历年龄,即使校正衰弱和其他既定风险因素后仍如此。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapy has transformed the treatment landscape of multiple myeloma (MM), a hematological cancer predominantly affecting older individuals. Yet, whether immune aging, shaped by intrinsic aging processes, genetics, and external factors, affects treatment efficacy remains unclear. To address this, we investigated the influence of age on the immune system in patients with MM and explored whether immune aging associates with clinical outcomes in older patients. Using flow cytometry, we conducted high-dimensional profiling of T cells and natural killer cells in peripheral blood and bone marrow samples of 124 older (>65 years) and 145 younger (≤65 years) patients with newly diagnosed MM (ages 34-92 years) enrolled in the HOVON-143 and CASSIOPEIA/HOVON-131 trials. On average, older patients exhibited a more activated, differentiated, and senescent T-cell compartment than younger patients. Nonetheless, substantial interindividual variation in T-cell subset frequencies within both age groups indicated that calendar age inadequately reflects an individual's immune status. We therefore developed an immune clock on high-dimensional phenotypic T-cell data to quantify each patient's "immune age," revealing substantial variation in immune ages among patients of similar calendar age. Importantly, immune age appeared a stronger predictor of clinical outcomes than calendar age in older, nonfit patients with newly diagnosed MM receiving daratumumab-ixazomib-dexamethasone, even after adjusting for frailty and other established risk factors. Overall, these findings highlight immune age as a clinically relevant composite metric that better reflects a patient's immune status than their calendar age. Validating this methodology in other immunotherapy settings may improve our ability to predict immunotherapy efficacy in older patients with MM or other hematological cancers.
引用
- Bruins WSC, Smits F, Duetz C, et al. A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy. Blood. 2025. PMID: 40829164. doi:10.1182/blood.2025028587
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。